Quince Therapeutics (QNCX) investor relations material

Executive summary

• Lead drug candidate eDSP failed to meet primary and secondary endpoints in the Phase 3 NEAT trial for A-T, resulting in the cessation of its development and no other current product candidates in the pipeline.

• The company is focused on preserving cash and evaluating strategic alternatives, including a potential reverse merger, after engaging LifeSci Capital as exclusive financial advisor.

• Net income for Q1 2026 was $35.9 million, driven by non-cash items, despite an accumulated deficit of $424.5 million as of March 31, 2026.

Financial highlights

• Q1 2026 net income was $35.9 million, compared to a net loss of $15.0 million in Q1 2025, primarily due to fair value adjustments and impairment charges.

• Operating expenses included a $67.8 million intangible asset impairment charge and a $64.3 million fair value adjustment for contingent consideration.

• Cash and cash equivalents were $18.2 million as of March 31, 2026, with an additional $5.4 million raised post-quarter via ATM equity sales.

• Research and development expenses decreased 16% year-over-year to $6.8 million, reflecting the wind-down of clinical activities.

• General and administrative expenses decreased 11% year-over-year to $4.3 million.

Outlook and guidance

• Cash and cash equivalents are not sufficient to fund operations for the next twelve months; additional funding is required.

• The company does not expect to generate revenue unless a strategic transaction, such as a reverse merger, is completed.

• Management has concluded that substantial doubt exists regarding the ability to continue as a going concern within one year.